UCB (OTCMKTS:UCBJY) Shares Gap Down – What’s Next?

UCB SA (OTCMKTS:UCBJY) gapped down prior to trading on Thursday . The stock had previously closed at $142.88, but opened at $124.64. UCB shares last traded at $123.53, with a volume of 4,924 shares.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on UCBJY shares. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a report on Monday, June 22nd. Zacks Research upgraded shares of UCB from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold”.

UCB Price Performance

The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04. The company has a fifty day simple moving average of $144.07 and a two-hundred day simple moving average of $147.71.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.